✨
AI Summary
- Risankizumab maintains high skin clearance rates for psoriasis.
- 52-week data from UnlIMMited trial presented at EADV Congress.
- No new safety signals observed for scalp and genital psoriasis treatment.
Guests on This Episode
CB
Christopher G. Bunick
1 podcast appearance